JP2014043405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014043405A5 JP2014043405A5 JP2012185867A JP2012185867A JP2014043405A5 JP 2014043405 A5 JP2014043405 A5 JP 2014043405A5 JP 2012185867 A JP2012185867 A JP 2012185867A JP 2012185867 A JP2012185867 A JP 2012185867A JP 2014043405 A5 JP2014043405 A5 JP 2014043405A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- ala
- region
- therapeutic agent
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 64
- 230000027455 binding Effects 0.000 claims 52
- 125000003275 alpha amino acid group Chemical group 0.000 claims 38
- 239000003814 drug Substances 0.000 claims 27
- 229940124597 therapeutic agent Drugs 0.000 claims 27
- 239000000427 antigen Substances 0.000 claims 22
- 102000036639 antigens Human genes 0.000 claims 22
- 108091007433 antigens Proteins 0.000 claims 22
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 16
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 16
- 230000002378 acidificating effect Effects 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 5
- 230000007935 neutral effect Effects 0.000 claims 5
- 208000014644 Brain disease Diseases 0.000 claims 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims 3
- 229910001424 calcium ion Inorganic materials 0.000 claims 3
- 102000009490 IgG Receptors Human genes 0.000 claims 2
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 210000005013 brain tissue Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012185867A JP6280300B2 (ja) | 2012-08-24 | 2012-08-24 | 脳疾患治療剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012185867A JP6280300B2 (ja) | 2012-08-24 | 2012-08-24 | 脳疾患治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014043405A JP2014043405A (ja) | 2014-03-13 |
| JP2014043405A5 true JP2014043405A5 (enExample) | 2015-10-01 |
| JP6280300B2 JP6280300B2 (ja) | 2018-02-14 |
Family
ID=50394958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012185867A Active JP6280300B2 (ja) | 2012-08-24 | 2012-08-24 | 脳疾患治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6280300B2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2017117464A1 (en) * | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| KR102777127B1 (ko) | 2016-08-02 | 2025-03-07 | 비스테라, 인크. | 조작된 폴리펩티드 및 그의 용도 |
| JP2022514290A (ja) * | 2018-12-20 | 2022-02-10 | ジェネンテック， インコーポレイテッド | 改変抗体ｆｃおよび使用方法 |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX365235B (es) * | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
-
2012
- 2012-08-24 JP JP2012185867A patent/JP6280300B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2993423C (en) | Il-8-binding antibodies and uses thereof | |
| CN107614529B (zh) | Pd-l1抗体、其抗原结合片段及其医药用途 | |
| JP2021091701A (ja) | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 | |
| JP2014043405A5 (enExample) | ||
| JP2020517287A5 (enExample) | ||
| CN105188872B (zh) | 用于纯化抗体的方法 | |
| JP2012515556A5 (enExample) | ||
| RU2017144098A (ru) | Гетеродимеризованный полипептид | |
| TW201116625A (en) | Readily isolated bispecific antibodies with native immunoglobulin format | |
| CN111320693B (zh) | 抗EphA4抗体 | |
| RU2011135422A (ru) | Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний | |
| JP2014524733A5 (enExample) | ||
| WO2015032906A4 (en) | Cd70-binding peptides and method, process and use relating thereto | |
| HRP20221142T1 (hr) | Modificirana igg protutijela koja se vežu na transformirajući faktor rasta beta1 s visokim afinitetom, avidnošću i specifičnošću | |
| CN103459427B (zh) | 针对人IgG抗体的CH1结构域中表位的抗原结合蛋白 | |
| WO2017134440A2 (en) | Heterodimers and purification thereof | |
| EP2830660A1 (en) | Anti-sema4d antibodies and epitopes | |
| JPWO2020004492A5 (enExample) | ||
| RU2019123112A (ru) | Анти-il-5 антитела | |
| JP2025146842A (ja) | 抗ｇａｌ９免疫阻害性結合分子 | |
| KR20210015898A (ko) | Nav1.7 모노클로날 항체 | |
| CN113993534A (zh) | 针对iRhom2的蛋白结合物 | |
| CN105658228A (zh) | 结合人类补体c5的稳定多肽 | |
| WO2019040791A1 (en) | MULTIVALENT AGONIST ANTIBODY CONSTRUCTS AGREEING RECEPTORS | |
| JP2025526384A (ja) | 新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド |